

A comprehensive review of formulation strategies, statistical designs and regulatory considerations in the QbD roadmap in nanotechnology

Ms. Disha Raju Nara¹, Dr. Priti Patel¹, Dr. L. H. Hiranandani¹

Department of Pharmaceutical Quality Assurance, 1College of Pharmacy, Thane, Maharashtra, India.

✉ Corresponding author: priti.patel@dlhcop.org

Doi: <https://doi.org/10.5281/zenodo.22301353>

Received: 8 July 2026

Accepted: 18 July 2026

Abstract:

Nanotechnology has greatly enhanced the delivery of pharmaceutical drugs by improving solubility, stability, bioavailability and therapeutic effectiveness. However, the creation of nanoformulations is still problematic as even little differences in composition or production circumstances may greatly alter the quality of the output. Quality by Design (QbD) and Design of Experiments (DoE) have become obligatory approaches for the production of robust, repeatable nanoformulations [1-3]. This study addresses the use of QbD and DoE to the major nano-drug delivery platforms including polymeric nanoparticles, liposomes, solid lipid nanoparticles, nanoemulsions, nanosuspensions, dendrimers and polymeric micelles. 1. Critical review of main QbD components (QTPP, CQAs, CMAs, CPPs) 2. Risk assessment techniques 3. Experimental design approaches 4. Process Analytical Technology (PAT) 5. Present-day regulatory requirements from FDA, EMA and ICH The integration of QbD and DoE is emphasized as critical to provide consistent product quality, regulatory approval and effective lab-to-market translation of nanomedicines

Keywords: Nanotechnology, Quality by Design, Design of Experiments, Nanoparticles, Drug Delivery, Critical Quality Attributes, Regulatory Requirements, Optimization.

Introduction: Nanotechnology has revolutionized medication delivery by allowing invention of nanoscale carriers (1-1000 nm) that may enhance drug solubility, increase bioavailability, enable tailored distribution and minimize systemic toxicity [8]. These features have resulted in the broad use of nanomedicines spanning cancer, infectious disorders, neurology and chronic illness management. Polymeric nanoparticles, liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), nanosuspensions, nanoemulsions, dendrimers and polymeric micelles are different platforms with unique formulation-performance connections.

Nanoformulations are complex systems with interdependent variables such particle size, zeta potential, encapsulation efficiency, drug release profile etc. which are sensitive to slight changes in material composition or processing conditions. Classical trial-and-error development methodologies do not well capture these linkages, which leads to poor repeatability and limited process comprehension. To overcome these limitations, the pharmaceutical sector and regulatory authorities have embraced QbD, where quality is designed into the product throughout development and not tested into the finished product [1]. DoE is a systematic statistical approach that offers the experimental framework to discover essential factors, predict their relationships and improve formulation performance. This study methodically highlights theoretical basis of QbD/DoE, nanoformulation platforms, optimization tools, PAT integration and current worldwide regulatory needs.

Quality by Design Approach for Nanoformulation Development:

Basic QbD Elements: Based on the ICH Q8(R2), Q9, and Q10 [1-3], the QbD framework includes a collection of organized components that collectively characterize and regulate product quality throughout the development

lifecycle.




Figure 1: QBD Workflow.

The Quality Target Product Profile (QTPP) outlines the desirable qualities of the completed product, such as dosage form, method of administration, drug release profile, stability and bioavailability objectives, and acts as the development anchor ^[1]. Critical Quality Attributes (CQAs) are the quantifiable product attributes that need to be within limitations to ensure safety and effectiveness. The CQAs for nanoformulations generally comprise particle size and polydispersity index (PDI), zeta potential, drug loading and encapsulation efficiency (EE%), in vitro drug release profile and sterility/endotoxin levels for parenteral products ^[6, 7]. Critical Material Attributes (CMAs) are features of input material such polymer molecular weight, lipid composition, surfactant type, medication solubility etc. which affect the CQAs. Critical Process Parameters (CPPs) are industrial process factors (such as homogenization speed, sonication time, stirring rate, processing temperature) that influence CQAs ^[4]. The mechanistic heart of QbD-based nanoformulation development is the systematic identification and regulation of CMAs and CPPs.

Tools for Risk Assessment: The risk assessment determines and ranks which CMAs and CPPs are most likely to have an influence on product quality ^[2]. Tools commonly used include: Failure Mode and Effects Analysis (FMEA) – ranks risks by severity, occurrence and detectability; Ishikawa (Fishbone) Diagram – maps root causes of quality variability; Risk Ranking and Filtering (RRF) – prioritizes issues for further study; Fault Tree Analysis (FTA) – traces cause and effect pathways leading to product failure. These strategies allow the experimental resources to be focused on the most influential factors, hence increasing efficiency and regulatory defensibility ^[5].

Nanoengineered Drug Delivery Systems:

Nanoparticles based on polymers: Polymeric nanoparticles, made from biodegradable polymers such as PLGA, PLA, chitosan, albumin and polycaprolactone, are one of the most researched nanocarriers owing to their biocompatibility, tunable breakdown and varied drug loading capacity ^[1, 2]. The main techniques of preparation include nanoprecipitation, emulsification-solvent evaporation, salting-out and ionic gelation. Formulation critical factors include polymer content, stabilizer type and concentration, organic/aqueous phase ratio, stirring speed and pH. Primary CQAs are particle size, PDI, encapsulation efficiency and drug release profile ^[7].

Solid lipid nanoparticles and nanostructured lipid carrier: SLNs and NLCs take use of the benefits of lipid-based systems such as increased stability, biocompatibility and controlled drug release. NLCs are produced by incorporating liquid lipid into the solid lipid matrix, and overcome the major drawback of SLNs, i.e. ejection of medication during storage ^[1]. Preparation is normally via high-pressure homogenization, microemulsion methods or solvent emulsification. The main CPPs influencing the particle size, stability and drug loading are the lipid composition, surfactant content, homogenization conditions and cooling rate ^[2, 7].

Liposomes: Liposomes are phospholipid bilayer vesicles that can encapsulate both hydrophilic (aqueous core) and lipophilic (bilayer membrane) medicines. They are still the most therapeutically effective nanocarrier platform. They may be prepared using thin film hydration, ethanol injection, reverse-phase evaporation or microfluidic synthesis. The CQAs include vesicle size, EE%, zeta potential and membrane stability. Lipid composition, cholesterol content, hydration conditions and extrusion parameters are important CQAs/CPPs ^[3].

Nanosuspensions and Nanoemulsions: Nanoemulsions are oil-in-water nanoscale dispersions stabilized by surfactants to improve solubility and bioavailability of BCS Class II/IV pharmaceuticals and are suitable for oral, topical or parenteral administration. High-energy procedures (ultrasonication, high-pressure homogenization) or low-energy methods (spontaneous emulsification) are utilized; oil content, choice of surfactant and energy input crucially affect droplet size and stability ^[7]. Nanosuspensions are drug nanoparticles stabilized by polymers or surfactants and provide a means for direct bioavailability increase of poorly soluble medicines by increasing surface area. Production comprises media grinding, high pressure homogenization, precipitation or hybrid top-down/bottom-up techniques ^[5].

Polymeric Micelles and Dendrimers: Dendrimers are hyper-branched monodisperse macromolecules with well-defined architecture and multivalent surface groups that allow efficient drug loading, targeted delivery and surface functionalization. The most investigated are PAMAM dendrimers, where the main factors of the formulation are generation number, surface modification, drug to dendrimer ratio and pH ^[7]. Polymeric micelles are self-assembled nanostructures of amphiphilic block copolymers; the hydrophobic core may solubilize weakly water-soluble medicines, while the hydrophilic corona offers steric stability and extended circulation. Micelle size, drug loading and release behavior are determined by polymer composition, molecular weight, drug-to-polymer ratio and solvent removal conditions ^[7].




Figure 2: QbD- DOE integration in Nanotechnology based drug delivery system

Experimental Designs for Screening: Screening designs are used to determine the most relevant variables from a vast set of possible factors in early development. Plackett-Burman Design (PBD) allows assessment of N-1 components in N runs (a multiple of 4) which is particularly efficient for identification of primary impacts ^[9]. Fractional Factorial Designs (FFD) test many variable combinations using a fraction of full factorial runs, determining the main impacts when several formulation and process factors need to be studied simultaneously ^[9]. These approaches are especially useful for nanoformulations where five to ten factors may affect CQAs concurrently. ^[16, 7]

Response Surface Methodology: Response surface methodology (RSM) uses quantitative models to establish relationships between independent variables and responses after initial variable screening, allowing for optimization. The Central Composite Design (CCD) is used extensively in optimization studies of nanoparticles ^[9] and allows the calculation of linear, interaction and quadratic effects. The Box-Behnken Design (BBD) takes less number of runs than CCD, avoids extreme factor combinations and is especially suited to pharmaceutical formulations where certain extreme circumstances are unfeasible ^[6]. Computationally produced D-optimal designs may handle uneven design spaces or limited experimental locations. Mixture designs are used for formulations where the proportions of the components should accumulate to a constant value, e.g. nanoemulsions, lipid nanoparticles, and liposomes ^[17, 18].

More Advanced Optimization Methods: Recent improvements in computational and data-driven technologies have been used to the optimization of nanoformulations. Definitive Screening Designs (DSD) can identify both main and quadratic effects effectively with fewer runs than typical RSM designs. Artificial Neural Networks (ANN) have been shown to be useful for simulating complicated non-linear formulation-response relationships. Bayesian optimization is an information adaptive, sequential approach for minimizing experimental effort. Machine learning methods can estimate formulation performance from massive multi-dimensional datasets ^[16]. These technologies are complementary to classical DoE and are increasingly included in high-throughput formulation development operations ^[16].

Design Space and Control Strategy: A design space is the multidimensional collection of input factors and process parameters that have been proved to assure product quality ^[1, 18]. Operating inside the design area is not a regulation change, offering great production freedom. The control method, including of raw material standards, in-process monitoring, process analytical technology (PAT) tools and finished-product testing, turns design space information into robust regular production ^[18].

Process Analytical Technology for Nanoformulation Production: Process Analytical Technology (PAT) is a fundamental part of the QbD architecture that provides real-time sensing and feedback control of industrial processes ^[1]. Real-time assessment of particle size and PDI is possible using Dynamic Light

Scattering (DLS). Focused Beam Reflectance Measurement (FBRM) is used to detect particle development and agglomeration. NIR and Raman spectroscopy are used to evaluate drug content, crystallinity and molecular interactions during processing. UV-Visible spectra, drug encapsulation, and release [7]. The increasing acceptance of continuous production has increased the strategic relevance of PAT. Real-time analytics in continuous production systems minimize batch-to-batch variability, allowing quick scale-up and allow for real-time release testing. Continuous production of liposomes and polymeric nanoparticles with highly repeatable size distributions has been achieved using microfluidic platforms and integration with PAT tools meet the current FDA and EMA standards for quality-driven manufacturing [13, 14].

Regulatory Frameworks for Nanomedicines:

Requirements of the FDA and EMA: The FDA recommends a complete QbD-based development of nanomedicines which necessitates detailed assessment of particle size, surface features, drug loading, release properties, stability and safety profiles. For liposomal formulations and other sophisticated nanotechnology-based therapies, product-specific advice has been published [13]. The EMA has released reflection papers on quality, safety and effectiveness standards for nanomedicines, with special attention on physicochemical characterisation, process validation, stability and evidence of bioequivalence for follow-on nanomedicine products [14, 19]. In 2011, FDA and EMA initiated a cooperative pilot program for simultaneous review of QbD applications to support harmonized implementation of ICH Q8–Q11 across countries [19].

ICH Guideline Landscape: The main ICH guidelines that govern the development of QbD-based nanoformulations are: ICH Q8(R2)—Pharmaceutical Development [1]; ICH Q9—Quality Risk Management [2]; ICH Q10—Pharmaceutical Quality System [3]; ICH Q11—Development and Manufacture of Drug Substances [4]; ICH Q12—Lifecycle Management [5]; and ICH Q3C—Residual Solvents. These principles together support methodical, risk-based, science-driven product development from early-stage through post-approval lifecycle management.

Challenges in Bioequivalence and Characterization: Nanomedicines need to undergo detailed physicochemical characterization for regulatory approval such as particle size distribution, zeta potential, surface morphology, drug loading, EE%, in vitro drug release profile, physical and chemical stability, residual solvent levels, and structural/crystallinity analysis. Safety tests may involve cytotoxicity, immunogenicity, hemolysis, biodistribution and repeat dosage toxicity studies [13, 14]. The demonstration of bioequivalence for generic nanomedicines is challenged by the fact that therapeutic performance is dependent on nanocarrier features (particle size, surface charge, drug release kinetics) that cannot be fully characterized by conventional pharmacokinetic endpoints alone, in contrast to small-molecule drugs. Regulatory authorities have demanded more and more extensive physicochemical characterisation in addition to in vitro research and pharmacokinetic investigations [14].

Nanotoxicology Aspects: The nanoscale of drug delivery systems affects biological interactions in ways that are not predictable by traditional toxicology. Key issues include protein corona formation that alters biodistribution, complement activation, storage in organs and ability of nanoparticles to cross biological barriers (blood–brain barrier, gastrointestinal epithelium) [7,8]. Factors must be thoroughly assessed throughout preclinical development to provide sufficient safety profiles for regulatory submission.

Conclusion: Nanotechnology is breaking barriers in medication delivery and solving long-standing problems of low solubility, fast clearance and non-specific distribution. However, translation of promising nanoformulations into robust, repeatable and economically viable products needs a disciplined development technique. QbD offers the conceptual and regulatory framework for understanding and controlling the interactions among material characteristics, process parameters and product performance, whereas DoE provides the statistical machinery for effective navigation of formulation space and building predictive models [1, 6, 9]. The combined use of QbD and DoE allows one to develop nanoformulations with well-defined design spaces, rational control techniques and predictable quality features, which are scientifically sound and regulatorily defensible [18, 19]. Simultaneous progress in PAT, continuous production and computational optimization techniques such as ANN and Bayesian methods are speeding up the translation of nanomedicines from the research to the commercial goods [16]. As the regulatory landscape continues to advance, the combination of scientific knowledge, statistical optimization, and proactive quality control will continue to be essential to the successful development and approval of next-generation nanomedicine products.

References:

1. Arriagada F, Enriquez-Palma A, Celis-Arias V, Carril-Garcia P, Dörner-Argomedeo V, González-Silva C, et al. Lipid-based nanocarriers for ocular administration: towards realization of experimental design. *Pharmaceutics*. 2021;13(4):447. doi:10.3390/pharmaceutics13040447.
2. Cao L, Russo D, Felton K, Salley D, Sharma A, Keenan G, et al. DoE of formulations by use of machine learning driven robotic experimentation. *Cell Rep Phys Sci*. 2023;4(7):100995. 2021;2(1):100295. doi:10.1016/j.xcrp.2020.100295.
3. EMA. European Medicines Agency. Reflection Paper on the Data Requirements for Intravenous Liposomal Products Developed with Reference to an Innovator Liposomal Product EMA/CHMP/806058/2009/Rev.02 . 2013.
4. European Medicines Agency and US Food and Drug Administration. EMA-FDA pilot programme for parallel review of Quality-by-Design applications 2013. Available from: <https://www.ema.europa.eu/en/human-regulatory/research-development/quality/quality-design>.
5. Food and Drug Administration (FDA), US. Guidance for Industry: Liposome Drug Products—Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling. CDER. 2018.
6. Ghose D, Patra CN, Ravi Kumar BVV, Swain S, Jena BR, Choudhury P, et al. Optimization of formulation and characterisation of polymeric nanoparticles of cinacalcet hydrochloride with enhanced biopharmaceutical properties using QbD approach. *Turk J Pharm Sci*. 2021;18(4):452–464. doi:10.4274/tjps.galenos.2020.08522.
7. Gurba-Bryśkiewicz, L., Maruszak, W., Smuga, D. A., Dubiel, K., & Wieczorek, M. (2023). Quality by Design (QBD) and Design of Experiments (DOE) as a strategy for tuning lipid nanoparticle formulations for RNA delivery. *Biomedicines*, 11(10), 2752. <https://doi.org/10.3390/biomedicines11102752>
8. Gurba-Bryśkiewicz, L., Maruszak, W., Smuga, D. A., Dubiel, K., & Wieczorek, M. (2023). Quality by Design (QBD) and Design of Experiments (DOE) as a strategy for tuning lipid nanoparticle formulations for RNA delivery. *Biomedicines*, 11(10), 2752. <https://doi.org/10.3390/biomedicines11102752>
9. International Council for Harmonisation. (2005). Quality risk management: ICH harmonised tripartite guideline Q9 [International Council for Harmonisation]. ICH Quality Guidelines. [1, 2, 3, 4]
10. International Council for Harmonisation. (2008). Pharmaceutical quality system: ICH harmonised tripartite guideline Q10 [International Council for Harmonisation]. ICH Quality Guidelines. [1, 2, 3]
11. International Council for Harmonisation. (2009). Pharmaceutical development: ICH harmonised tripartite guideline Q8(R2) [International Council for Harmonisation]. ICH Quality Guidelines. [1, 2]
12. International Council for Harmonisation. (2011). Development and manufacture of drug substances (chemical entities and biotechnological/biological entities): ICH harmonised tripartite guideline Q11 [International Council for Harmonisation]. ICH Quality Guidelines. [1, 2, 3, 4, 5]
13. International Council for Harmonisation. (2019). Technical and regulatory aspects of pharmaceutical product lifecycle management: ICH harmonised tripartite guideline Q12 [International Council for Harmonisation]. ICH Quality Guidelines. [1, 2, 3]
14. Jain A, Jain SK. Design and optimization of chitosan nanoparticles for colon cancer treatment. *J Biomater Appl*. 2019;33(7):879–894. 10.1177/0885328218809855.

15. Liu T, Yu X, Yin H. Study of top-down and bottom-up techniques by applying design of experiment (DoE) for the manufacture of nanosuspension. *Drug Dev Ind Pharm.* 2019;45(3):434–444. doi:10.1080/03639045.2018.1545787.
16. Maione-Silva, L., De Castro, E. G., Nascimento, T. L., Cintra, E. R., Moreira, L. C., Cintra, B. a. S., Valadares, M. C., & Lima, E. M. (2019). Ascorbic acid encapsulated into negatively charged liposomes exhibits increased skin permeation, retention and enhances collagen synthesis by fibroblasts. *Scientific Reports*, 9(1), 522. <https://doi.org/10.1038/s41598-018-36682-9>
17. Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MNV. Estradiol loaded PLGA nanoparticles for oral administration: influence of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. *J Control Release.* 2007;119(1):77–85. doi:10.1016/j.jconrel.2007.01.016
18. Politis SN, Colombo P, Colombo G, Rekkas DM. Design of experiments (DoE) in pharmaceutical development. *Drug Dev Ind Pharm.* 2017;43(6):889–901. doi: 10.1080/03639045.2017.1291578.
19. Politis SN, Rekkas DM. Design space and control approach for the development and manufacturing of drug nanoparticles. *Pharmacy.* 2019;11(7):322. doi:10.3390/pharmaceutics11070322.
20. Singh M, Raghav S, Chavda V, Singh P, Yadav SK, Kim W et al. Recent advances, possibilities and problems in next generation nanocarriers for improvement of solubility and targeted delivery of drugs. *Nano Trends* 2026;13:100183. doi:10.1016/j.nwnano.2026.100183.